CurrentCignaPolicy N/A

Zycubo (copper histidinate) coverage criteria for Menkes disease

Defines prior authorization, documentation, and medical necessity criteria for coverage of Zycubo (copper histidinate subcutaneous injection) for treatment of Menkes disease in pediatric patients under Cigna-administered benefit plans.

Policy Summary

PayerCigna

PolicyZycubo (copper histidinate) coverage criteria for Menkes disease

Policy CodePolicy N/A

Change TypeSpecialist requirement revised (neonatologist added)

Effective DateN/A

Next Review DateFeb 4, 2026

Key ActionObtain prior authorization and ensure prescription is by or in consultation with a geneticist, neonatologist, neurologist, or Menkes disease specialist.

SourceLink

POLICY UPDATE CHANGES

The specialist requirement was updated to include a neonatologist.

1 yearInitial approval duration

1 monthPresumed diagnosis approval

Not coveredOccipital Horn Syndrome (OHS)

Prior Auth recommendedCoverage requirement

Coverage and Medical Necessity Criteria

Initial FDA-Approved Indication

Covered when ALL of the following are met

Menkes disease indication

Diagnosis confirmation: One of: (i) molecular genetic test demonstrating a pathogenic or likely pathogenic ATP7A variant; OR (ii) plasma catecholamine analysis findings consistent with Menkes disease; OR (iii) prescriber documents findings suggestive of Menkes disease with genetic or catecholamine testing in progress.
If (i) or (ii) approval duration = 1 year; if (iii) approval duration = 1 month.

refDescriptorNotUsedHere_qmReplaceRef_b0_0_qmReplaceRef_b0_0_ref_qm_b0_0_ref_not_allowed_b0_0_ref_b0_0_ref_exact_echo_b0_0_ref_b0_0_ref_echo_b0_0_ref_b0_0_ref_echo_b0_0_ref_b0_0_ref_echo_b0_0_ref_b0_0_ref_b0_0_ref_b0_0_ref_b0_0_ref_b0_0_ref_b0_0_ref_b0_0_ref_b0_0_ref_b0_0_ref_b0_0_ref_b0_0_ref_b0_0_ref_b0_0_ref_b0_0_ref_b0_0_ref_b0_0_ref_b0_0_ref_b0_0_ref_b0_0_ref_b0_0_ref_b0_0_ref_b0_0_ref_b0_0_ref_b0_0_ref

Zycubo (copper histidinate) is not indicated and is considered not medically necessary for treatment of Occipital Horn Syndrome (OHS), a milder phenotype of ATP7A-related disease.

Policy Summary

PayerCigna

PolicyZycubo (copper histidinate) coverage criteria for Menkes disease

Policy CodePolicy N/A

Change TypeSpecialist requirement revised (neonatologist added)

Effective DateN/A

Next Review DateFeb 4, 2026

Key ActionObtain prior authorization and ensure prescription is by or in consultation with a geneticist, neonatologist, neurologist, or Menkes disease specialist.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Prior Authorization, Documentation, and Billing Guidance

Prior Authorization

Prior Authorization Required

Prior authorization is recommended for Zycubo (copper histidinate). Approvals require the medication to be prescribed by or in consultation with a geneticist, neonatologist, neurologist, or a specialist who focuses on treatment of Menkes disease.

Prior authorization recommended for prescription benefit coverage of Zycubo.
Approvals require prescription by or in consultation with a specialist (geneticist, neonatologist, neurologist, or specialist focusing on Menkes disease).

Documentation Required

Diagnostic Documentation Required

Providers must submit diagnostic documentation to support the diagnosis of Menkes disease. Acceptable confirmation includes molecular genetic testing showing a pathogenic or likely pathogenic ATP7A variant or plasma catecholamine analysis consistent with Menkes disease (plasma dopamine/norepinephrine ratio > 0.2 or DOPAC/DHPG ratio > 5). If testing is pending, a prescriber attestation of findings suggestive of Menkes disease may allow a 1-month approval while testing is in progress.

Molecular genetic test demonstrating pathogenic/likely pathogenic ATP7A variant — approval duration: 1 year.
Plasma catecholamine analysis consistent with diagnosis (dopamine/norepinephrine ratio > 0.2 or DOPAC/DHPG ratio > 5) — approval duration: 1 year.
If presumed diagnosis with testing pending, approve for 1 month while genetic or plasma catecholamine testing is in progress.

Denial Risk

Denial Triggers and Not Covered Uses

Claims submitted without covered diagnosis or procedure codes consistent with this policy will be denied. Zycubo is not medically necessary and should not be billed for Occipital Horn Syndrome or any other non‑covered uses.

Claims lacking covered codes under the applicable coverage policy will be denied as not covered.
Zycubo is considered not medically necessary for Occipital Horn Syndrome and other non‑listed indications.

Note

Provider Action and Approval Durations

When requesting approval, include the prescriber's specialty and documentation of diagnostic testing or test pending status. Approvals are time-limited as specified: 1 year for confirmed genetic or catecholamine diagnosis; 1 month for presumed diagnosis with testing pending. Continue treatment indefinitely as clinically indicated per specialty guidance.

Include prescriber specialty (geneticist, neonatologist, neurologist, or Menkes specialist) with prior authorization request.
Approval durations: 1 year for confirmed diagnosis (genetic or catecholamine); 1 month if testing pending.
Clinical guidance recommends early initiation (neonatal period) and continued long-term treatment for classical Menkes disease.

Definitions and Diagnostic Thresholds

Occipital Horn Syndrome (OHS)

Definition of Occipital Horn Syndrome (OHS)A milder phenotype of ATP7A-related disease (Menkes disease).

Coverage stance for OHSZycubo is not indicated for the treatment of Occipital Horn Syndrome (OHS).

ImplicationUse of Zycubo for OHS is considered not medically necessary and excluded from coverage for indications other than Menkes disease.

Diagnostic plasma catecholamine thresholds

Plasma dopamine/norepinephrine ratio diagnostic threshold> 0.2

Plasma DOPAC/DHPG ratio diagnostic threshold> 5

Use in diagnostic workflowThese plasma catecholamine thresholds are recognized diagnostic criteria and may confirm a presumed diagnosis when genetic testing is unavailable; plasma analysis is not available at all centers.

OpenPayer

Zycubo (copper histidinate) coverage criteria for Menkes disease

Coverage and Medical Necessity Criteria

Coding and Diagnostic Criteria

Prior Authorization, Documentation, and Billing Guidance

Background and Scope

Definitions and Diagnostic Thresholds